June 15, 2022, Correctseq got prize of “2022 Top 50 Biotech Innovation Companies” from KPMG. On the prize list, more than half of companies have 5 years histories, 89% companies have more than 3 years histories, only 4 companies have less than 2 years histories and Correctseq is one of them. Correctseq is evaluated to be the most potential company in the gene therapy fields because of its innovative gene editing technology.
Correctseq is born with innovation. The scientific co-founders of Correctseq focus on the frontier of gene editing field. They developed a series of innovative gene editing technology which can correct the mutated base gene precisely and permanently without making double-strand DNA break and off-target mutations, containing a transformer base editor with ultra-high editing precision that eliminated both gRNA-dependent and gRNA-independent off-target mutations (tBE, Nature Cell Biology, 2021), the dCas12a base editor that does not activate the DNA damage response pathway (BEACON, Cell Reports, 2020), a Cpf1 base editor for efficient editing within the genome A/T-enriched region (dCpf1-BE, Nature Biotechnology, 2018a) and a universal Cas9 base editor with efficient editing in G/C-enriched region and hypermethylated region (hA3A-BE, Nature Biotechnology, 2018b), a higher and more efficient enhanced Cas9 base editor (eBE, Cell Research, 2017). enhanced Base Editor (eBE) is the first base editing tool authorized by Chinese patents in 2020 and hA3A-BE is also authorized by Chinese patents in 2021. Other base editors are applying PCT and in the evaluating period.
Correctseq is transforming its innovation gene editing technology into clinical therapies. Its multiple pipelines for genetic diseases, tumor immunotherapy, metabolic diseases, and infectious diseases based on the base editing technology are well underway. Recently, Correctseq is building an IND pipeline using tBE(transformer Base Editor) for β-thalassemia. Compared with Cas Nuclease gene editing therapy, tBE exhibits higher editing efficiency and γ-globin induction, lower cytotoxicity and no off-target mutations. Correctseq has gathered dozens of outstanding biomedical experts from the fields of gene editing R&D, new drug development, CMC development, clinical operation, quality, etc. The management team and R&D team have more than 10 years industrial experience, with more than 30% of the staff holding doctoral degrees. Correctseq focuses on biotechnology innovation, research and development and is committed to develop reliable and safe gene editing therapies efficiently for the whole world.
The selected activity titled “2022 Top 50 Biotech Innovation Companies” was organized by KPMG China in conjunction with professional institutions and industry experts. There were 5 evaluation standards containing weather the technology and product is cutting-edge, the corn management team and R&D team, the attention of investors, the diversity of pipelines and original product ratio, the health of finance. The activity abstracted experts from academia, industries, investment community, companies and so on from Aug., 2021. (KPMG China: The 1st Top 10 Biotech Innovation Companies Held Successfully)
Correctseq getting the prize of “2022 Top 50 Biotech Innovation Companies” gives recognition to its innovative gene editing technology. Correctseq will focus on biotechnology innovation, research and development and is committed to use innovative gene editing system to help people living with serious diseases.
About CorrectSequence Therapeutics
CorrectSequence Therapeutics aims to use our innovative gene editing system to help people living with serious diseases. We have developed multiple base editing systems and our base editors offer significant advantages in controlling off-target effects and improving in vivo editing efficiency. Multiple pipelines are well underway. The scientific co-founders of Correctseq focus on the frontier of gene editing field. Our R&D laboratory, CMC process development laboratory, and cGMP manufacturing facility are built with world-class standards, which strongly guarantees the rapid translation and application of our innovative research.